Heartware International (HTWR) : Traders are bullish on Heartware International (HTWR) as it has outperformed the S&P 500 by a wide margin of 0.03% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.13%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.1% in the last 1 week, and is up 0.42% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Heartware International Inc. is up 103.58% in the last 3-month period. Year-to-Date the stock performance stands at 15.08%. The stock has recorded a 20-day Moving Average of 0.13% and the 50-Day Moving Average is 12.4%.
Heartware International (NASDAQ:HTWR): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $57.96 and $57.96 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $58.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $58.00, notching a gain of 0.05% for the day. The total traded volume was 158,416 . The stock had closed at $57.97 on the previous day.
Also, Brokerage firm Leerink Swann downgrades its rating on Heartware International (NASDAQ:HTWR). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on July 11, 2016.
Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump, the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery, directly adjacent to the heart. The Companys hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of blood.